
Please verify your contribution to Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2

1 message

Vaccine <em@editorialmanager.com>

26 January 2022 at 01:07

Reply-To: Vaccine <support@elsevier.com>

To: Gatot Soegiarto <gatot_soegiarto@fk.unair.ac.id>

This is an automated message.

Journal: Vaccine

Title: Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2

Corresponding Author: Dr Delvac Oceandy

Co-Authors: Gatot Soegiarto; Laksmi Wulandari; Dewajani Purnomosari; Karin Dhia Fahmita; Hendra Ikhwan Gautama; Satrio Tri Hadmoko; Muhammad Edwin Prasetyo; Bagus Aulia Mahdi; Nur Arafah; Dewi Prasetyaningtyas; Pujo Prawiro Negoro; Cita Rosita Sigit Prakoeswa; Anang Endaryanto; Desak Gede Agung Suprabawati; Damayanti Tinduh; Eka Basuki Rachmad; Erwin Astha Triyono; Joni Wahyuhadi; Catur Budi Keswardiono; Feby Elyana Wardani; Fitriyah Mayorita; Nunuk Kristiani; Ari Baskoro; Deasy Fetarayani; Wita Kartika Nurani

Manuscript Number:

Dear Dr Gatot Soegiarto,

The corresponding author Dr Delvac Oceandy has listed you as a contributing author of the following submission via Elsevier's online submission system for Vaccine.

Submission Title: Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2

Elsevier asks all authors to verify their co-authorship by confirming agreement to publish this article if it is accepted for publication.

Please read the following statement and confirm your agreement by clicking on this link:

<https://www.editorialmanager.com/jvac/l.asp?i=992671&l=74AIW0MG>

I irrevocably authorize and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf (or, if the article is to be published under a CC BY license, a non-exclusive publishing agreement), in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights (or for CC BY articles a non-exclusive license of rights) to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article if it is accepted for publication shall apply and that this agreement is subject to the governing law of the country in which the journal owner is located.

If you did not co-author this submission, please contact the corresponding author directly at delvac.oceandy@manchester.ac.uk.

Thank you,
Vaccine

More information and support

FAQ: What is copyright co-author verification?

https://service.elsevier.com/app/answers/detail/a_id/28460/supporthub/publishing/

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?

https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/kw/editorial+manager/

For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by

phone and 24/7 by live chat and email.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/jvac/login.asp?a=r>). Please contact the publication office if you have any questions.

Rights and Access form Completed form for your article [JVAC_24053]

1 message

Elsevier - Author Forms <Article_Status@elsevier.com>
To: gatot_soegiarto@fk.unair.ac.id

27 May 2022 at 17:55


ELSEVIER

Dear Dr Soegiarto,

Thank you for publishing your article in Vaccine . Dr. Oceandy completed the Rights and Access Form for your article *Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2* on May 27, 2022.

The Order Summary is attached to this email. A copy of the Order Summary is also sent to all co-authors for whom we have contact details.


Your article will be free for everyone to read online within 24 hours at [https://authors.elsevier.com/sd/article/S0264-410X\(22\)00676-4](https://authors.elsevier.com/sd/article/S0264-410X(22)00676-4)



If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference JVAC24053 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support



Seven strategies for you to create a brand and promote your research

Learn how to give your research the visibility it deserves with these seven strategies.

> [Access module now](#)

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your

inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.



Order Confirmation.html

14K



Gatot Soegiarto <gatot_soegiarto@fk.unair.ac.id>

Corrections received - [JVAC_24053]

1 message

optteam@elsevierproofcentral.com <optteam@elsevierproofcentral.com>
To: gatot_soegiarto@fk.unair.ac.id

30 May 2022 at 16:53

This is an automatically generated message. Please do not reply because this mailbox is not monitored.

Dear Dr. Gatot Soegiarto, Delvac Oceandy,

Thank you very much for using the Proof Central application for your article "Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2" in the journal "JVAC"

All your corrections have been saved in our system. The PDF summary of your corrections, generated from Proof Central, can be downloaded from the following site for your reference:

https://pcv3-elsevier-live.s3.amazonaws.com/71c654cfff43ce668fbf12dcff252a/JVAC_24053_edit_report.pdf

To track the status of your article throughout the publication process, please use our article tracking service:

http://authors.elsevier.com/TrackPaper.html?trk_article=JVAC24053&trk_surname=

For help with article tracking:

http://support.elsevier.com/app/answers/detail/a_id/90

Kindly note that now we have received your corrections, your article is considered finalised and further amendments are no longer possible.

For further assistance, please visit our customer support site at <http://support.elsevier.com>. Here you can search for solutions on a range of topics. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

Yours sincerely,
Elsevier Proof Central team

When you publish in an Elsevier journal your article is widely accessible. All Elsevier journal articles and book chapters are automatically added to Elsevier's SciVerse Science Direct which is used by 16 million researchers. This means that Elsevier helps your research get discovered and ensures that you have the greatest impact with your new article.

www.sciencedirect.com

Dear Author, your article has been accepted

1 message

Vaccine <service@author.email.elsevier.com>
Reply-To: no-reply <no-reply@author.email.elsevier.com>
To: gatot_soegiarto@fk.unair.ac.id

30 May 2022 at 21:12

If you are unable to view this message correctly, [click here](#)



ELSEVIER

Congratulations on your accepted article!

Dear Author,

We recognize you have a choice of where to submit your research and we thank you for choosing to publish with *Vaccine*.

As an expert in the field, you are best placed to explain why your article, *Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2*, is interesting or impactful to a wider audience. Find out how you can help your article get the visibility it deserves:



Share and Publish your
Research Data



Researcher Academy



Get Noticed

We look forward to receiving future manuscripts from you!

Sincerely,

Researcher Engagement Team

Can we assist you with something? Visit our help page "

Elsevier supports responsible sharing:

Responsible sharing in line with copyright enables publishers to sustain high quality journals and the services they provide to the research community. [Find out how you can share your manuscript in Elsevier journals.](#)

- Find useful tools and resources: [Author Resources](#).
- For assistance, please visit our [Customer Support](#) site, where you can search for solutions on a range of topics and find answers to frequently asked questions.

Would you like to **update your information**? Amend your profile or publication history by visiting the [Scopus profile and content corrections Support Center](#).

If you do not wish to receive any further Service messages, please send us an [email](#).



This is a Service message, sent to you by Elsevier STM Journals.

Copyright © 2022 Elsevier Limited All rights reserved. | [Elsevier Privacy Policy](#)
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB UK

Share your article [JVAC_24053] published in Vaccine

1 message

Elsevier - Article Status <Article_Status@elsevier.com>
To: gatot_soegiarto@fk.unair.ac.id

31 May 2022 at 19:17




ELSEVIER

Share your article!

Dear Dr Soegiarto,

As co-author of the article *Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2*, we are pleased to let you know that the open access version of your article is now available online with author corrections incorporated. Full citation details, e.g. volume and/or issue number, publication year and page numbers, will be added when the final version becomes available.

The URL below is a quick and easy way to share your work with colleagues, other co-authors and friends. Anyone clicking on the link will be taken directly to the latest version of your article on ScienceDirect.



Your article link:

<https://doi.org/10.1016/j.vaccine.2022.05.059>

Click on the icons below to share with your network:



You can also use this link to download a copy of the article for your own archive. It also provides a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add it to your homepage or social media profiles, such as Facebook, Google+, and Twitter. Other ways in which you can use your final article have been determined by your choice of [user license](#).

To find out how else you can share your article visit www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support

Increase your article's impact

Our [Get Noticed](#) guide contains a range of practical tips and advice to help you maximize visibility of your article.

Publishing Lab

Do you have ideas on how we can improve the author experience? Sign up for the [Elsevier Publishing Lab](#) and help us develop our publishing innovations!

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](#) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.